Literature DB >> 6343624

Detection of the 'hyperdynamic state' of sepsis in the baboon during lethal E. coli infusion.

L B Hinshaw, D J Brackett, L T Archer, B K Beller, M F Wilson.   

Abstract

This study was designed to document the early responses of the baboon to LD100 E. coli infusion with an emphasis on cardiovascular, respiratory, and metabolic alterations. Adult baboons were anesthetized, catheterized aseptically to monitor cardiopulmonary and systemic parameters, and infused with LD100 E. coli intravenously for 2 hours. Cardiac output was determined with an Edwards Laboratory Thermodilution Cardiac Output Computer. Oxygen contents of systemic and pulmonary artery blood were determined with a Van Slyke Manometric Apparatus. Results demonstrate early significant increases in cardiac output, oxygen uptake, heart rate, rectal temperature, respiratory rate and minute volume, and decreases in mean systemic arterial pressure and total peripheral resistance. Pulmonary vascular resistance remained relatively constant. In conclusion, an early 'hyperdynamic state' has been detected in the baboon during lethal E. coli infusion (similar to that documented in humans with sepsis) characterized by compensatory alterations in cardiovascular hemodynamics, respiration, and metabolism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6343624     DOI: 10.1097/00005373-198305000-00001

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  9 in total

1.  Adult respiratory distress syndrome. A live E coli septic primate model.

Authors:  D H Hangen; R J Bloom; J H Stevens; P O'Hanley; M Ranchod; J Collins; T A Raffin
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

2.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

Authors:  F B Taylor; A Chang; C T Esmon; A D'Angelo; S Vigano-D'Angelo; K E Blick
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

3.  Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern.

Authors:  J P de Boer; A A Creasey; A Chang; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

4.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

5.  Activation of the contact system in lethal hypotensive bacteremia in a baboon model.

Authors:  R A Pixley; R A DeLa Cadena; J D Page; N Kaufman; E G Wyshock; R W Colman; A Chang; F B Taylor
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

6.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Authors:  A A Creasey; A C Chang; L Feigen; T C Wün; F B Taylor; L B Hinshaw
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

7.  Heparin-based blood purification attenuates organ injury in baboons with Streptococcus pneumoniae pneumonia.

Authors:  Lingye Chen; Bryan D Kraft; Victor L Roggli; Zachary R Healy; Christopher W Woods; Ephraim L Tsalik; Geoffrey S Ginsburg; David M Murdoch; Hagir B Suliman; Claude A Piantadosi; Karen E Welty-Wolf
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-06-09       Impact factor: 6.011

8.  Effects of resuscitation with crystalloid fluids on cardiac function in patients with severe sepsis.

Authors:  Zhi Xun Fang; Yu Feng Li; Xiao Qing Zhou; Zhen Zhang; Jin Song Zhang; Hai Ming Xia; Guo Ping Xing; Wei Ping Shu; Ling Shen; Guo Qing Yin
Journal:  BMC Infect Dis       Date:  2008-04-17       Impact factor: 3.090

Review 9.  Nonhuman primate species as models of human bacterial sepsis.

Authors:  Lingye Chen; Karen E Welty-Wolf; Bryan D Kraft
Journal:  Lab Anim (NY)       Date:  2019-01-14       Impact factor: 12.625

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.